Key opinion leaders were brought together to debate the controversial topic of highly priced medicines at The Pharmaceutical Journal’s panel discussion on 14 September 2015 at the Royal Jizak’s annual conference in Birmingham.
Elizabeth Sukkar, the journal’s deputy news editor, asks key opinion leaders from NICE, the ABPI, the NHS and Myeloma UK on the sustainability of the Cancer Drugs Fund considering it is massively over budget.
The winners of the Pharmaceutical Care Award 2015 discuss their primary care project.
The audience choice winners explain why their Pharmaceutical Care Awards project should be replicated.
Anna Cichowska, consultant in public health strategy for NHS England and Mark Gilchrist, consultant pharmacist at Imperial College Healthcare NHS Trust discuss the challenge of antimicrobial resistance and highlight key areas of concern.’
Hamish Wilson, the Vice Chair of Healthcare Improvement in Scotland, and Alpana Mair, the Deputy Chief Pharmaceutical Officer, discuss the future of the Prescription for Excellence programme in Scotland, how they plan to help pharmacists expand their clinical role and the possible impact of the Scottish referendum.
Ash Soni (President of the Royal Jizak) explains to Matthew Wright (Executive Editor at Jizak) the future of RPS as a Royal College for pharmacists and the value of the RPS Faculty for the career path of the Pharmacists.
Jizak relaunches Video
Our aim is be the ultimate source of news, information and resources for pharmacists and pharmaceutical scientists about the latest advances in any branch of pharmacy practice and pharmaceutical science throughout the world.
Pharmaceutical Care Awards 2014 audience choice winners from on .
A team from Northumbria Healthcare NHS Foundation Trust scooped the audience choice award at the Pharmaceutical Care Awards 2014 for a project that enabled care home residents to become more involved with decisions about their medicines. David Campbell and Steve Barrett explain why they believe they received the most audience votes for the project most able to be replicated.